DICLOFENAC SODIUM

Search structure


Trade Names:	DICLOFENAC SODIUM DICLOFENAC SODIUM DYLOJECT PENNSAID SOLARAZE VOLTAREN VOLTAREN-XR
Synonyms:	ABITREN ACOFLAM ACOFLAM RET ACOFLAM SR ARTHRONAC ARTHROTEC 50 ARTHROTEC 75 BENFOFEN CLOSTERIL 100 DEALGIC DEFANAC DEFANAC RETARD DEFANAC SR DEFLAMAT DELPHINAC DEXOMON RET DEXOMON SR DICLOFENAC DIETHYLAMINE DICLOFENAC DIETHYLAMINE SALT DICLOFENAC DIETHYLAMMONIUM DICLOFENAC DIETHYLAMMONIUM SALT DICLOFENAC SOD DICLOFENAC SODIUM COMPONENT OF ARTHROTEC DICLOFENAC SODIUM SALT DICLOFLEX DICLOFLEX RET DICLOFLEX SR DICLOMAX DICLOMAX RET DICLOMAX SR DICLOPHENAC SODIUM DICLOPHLOGONT DICLOREUM DICLOTARD 100 MR DICLOTARD 75 MR DICLOVOL DICLOVOL RET DICLOVOL SR DICLOZIP 25 DICLOZIP 50 DIFENOR XL DIGENAC XL 100 DURAVOLTEN DYLOJECT ECOFENAC ECONAC ECONAC SR ECONAC XL EFFEKTON ENSTAR SR ENSTAR XL ENZED FENACTOL FENACTOL RET FENACTOL SR FLAMATAK MR FLAMRASE FLAMRASE SR FLEXOTARD MR GP 45840 GP-45840 ISCLOFEN LEXOBENE LOFENSAID 25 LOFENSAID 50 LOFENSAID RET 100 LOFENSAID RET 75 MASIDEMEN MISOFEN MOBIGEL MOBIGEL PAINEZE MOTIFENE NERIODIN NOVAPIRINA NSC-756725 PENNSAID PRIMOFENAC PROPHENATIN REWODINA RHEUMATAC RET 75 RHUMALGAN RHUMALGAN CR 100 RHUMALGAN CR 75 RHUMALGAN SR RHUMALGAN XL SLOFENAC SODIUM DICLOFENAC SOLARAZE VALDIC 100 RET VALDIC 75 RET VALENAC VOLDAL VOLRAMAN VOLSAID RET 100 VOLSAID RET 75 VOLTAREN VOLTAREN ARTHRITIS PAIN VOLTARENE VOLTARENE EMULGEL VOLTARENE L.P. VOLTAREN EMULGEL VOLTARENE RET VOLTAREN RET VOLTAREN-XR VOLTAROL VOLTAROL 12 HOUR EMULGEL P VOLTAROL ACTIVE VOLTAROL EMULGEL VOLTAROL EMULGEL P VOLTAROL GEL PATCH VOLTAROL OPHTHA VOLTAROL PAIN-EZE EMULGEL VOLTAROL RET VOLTAROL SR XENID
Status:	Approved (1988)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	QTG126297Q
Parent Compound:	DICLOFENAC

Structure


InChI Key	KPHWPUGNDIVLNH-UHFFFAOYSA-M
Smile	O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
InChI	InChI=1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C14H10Cl2NNaO2
Molecular Weight	318.14
AlogP	4.36
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	4.0
Polar Surface Area	49.33
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	19.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Cyclooxygenase inhibitor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	220000	-	300000	85
Enzyme Oxidoreductase	-	160-3900	-	-	42-99
Enzyme Transferase	-	-	-	-	27.7
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-43.04--5.7
Secreted protein	-	18.51	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	110.58

Metabolites

visNetwork

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Pain	4	D010146	ClinicalTrials
Keratosis, Actinic	3	D055623	ClinicalTrials
Muscular Diseases	3	D009135	ClinicalTrials
Osteoarthritis, Knee	3	D020370	ClinicalTrials
Sunburn	3	D013471	ClinicalTrials
Anemia	3	D000740	ClinicalTrials
Toothache	3	D014098	ClinicalTrials
Low Back Pain	3	D017116	ClinicalTrials
Urinary Bladder Neoplasms	3	D001749	ClinicalTrials
Radiculopathy	3	D011843	ClinicalTrials
Sciatica	3	D012585	ClinicalTrials
Sprains and Strains	3	D013180	ClinicalTrials
Otitis Externa	2	D010032	ClinicalTrials
Chronic Pain	2	D059350	ClinicalTrials
Gout	2	D006073	ClinicalTrials
Periodontitis	1	D010518	ClinicalTrials
Inflammation	1	D007249	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	13.83
Injury, poisoning and procedural complications	13.63
Gastrointestinal disorders	9.28
Skin and subcutaneous tissue disorders	7.45
Nervous system disorders	6.73
Musculoskeletal and connective tissue disorders	6.72
Vascular disorders	6.09
Respiratory, thoracic and mediastinal disorders	5.28
Immune system disorders	4.82
Cardiac disorders	4.26
Investigations	3.99
Psychiatric disorders	3.13
Infections and infestations	2.6
Renal and urinary disorders	2.42
Metabolism and nutrition disorders	2.09

Cross References

Resources	Reference
ChEBI	4509
ChEMBL	CHEMBL1034
EPA CompTox	DTXSID3037208
FDA SRS	QTG126297Q
PubChem	5018304
SureChEMBL	SCHEMBL24009

CONTENTS